WO2024191848A2 - Peptides ciblant ckit utilisés comme agent thérapeutique et leurs procédés d'utilisation - Google Patents

Peptides ciblant ckit utilisés comme agent thérapeutique et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2024191848A2
WO2024191848A2 PCT/US2024/019186 US2024019186W WO2024191848A2 WO 2024191848 A2 WO2024191848 A2 WO 2024191848A2 US 2024019186 W US2024019186 W US 2024019186W WO 2024191848 A2 WO2024191848 A2 WO 2024191848A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
peptide
ckit
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/019186
Other languages
English (en)
Other versions
WO2024191848A3 (fr
Inventor
Adam Stein
Andre WATSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligandal Inc
Original Assignee
Ligandal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligandal Inc filed Critical Ligandal Inc
Priority to EP24771486.8A priority Critical patent/EP4676943A2/fr
Publication of WO2024191848A2 publication Critical patent/WO2024191848A2/fr
Publication of WO2024191848A3 publication Critical patent/WO2024191848A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the cKit gene encodes a receptor tyrosine kinase, also known as CD117, which has an N-terminal extracellular region with five immunoglobulin-like domains, a transmembrane region, and an intracellular tyrosine kinase domain at the C-terminus.
  • CD117 receptor tyrosine kinase
  • SCF stem cell factor
  • Disruptions in the cKit/SCF interaction have been linked to a variety of diseases, including cancer, autoimmune disorders, and gastrointestinal disorders.
  • Existing therapies targeting cKit suffer from low efficacy and off- target effects.
  • the present technology describes the use of a peptide as a cellular specific therapeutic agent for the targeted delivery of peptide therapeutics that specifically target the cKit/SCF binding surface.
  • the present technology provides SCF-derived peptides designed to specifically target cKit.
  • the peptides may include a sequence that binds to the extracellular domain of the cKit receptor, or to a proximal region distal to the extracellular domain, and binding of the peptides to cKit activates the receptor.
  • the peptides can be used on delivery vehicles (e.g., nanoparticles) as guides for efficient delivery of therapeutics to cells expressing the cKit receptor, resulting in specific modulation of cKit.
  • the peptide specifically targets cKit and comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1-73, or an amino acid sequence that is at least 80% identical to any one of SEQ ID NOs: 1-73.
  • the peptide is conjugated to one or more conditioning agents, for example, busulfan and/or saporin.
  • binding of the peptide to cKit results in altered signal transduction of cKit, for example, at least partially activating or at least partially inhibiting or blocking signal transduction of cKit.
  • the present technology provides a delivery vehicle conjugated to the peptide provided herein.
  • the delivery vehicle is a nanoparticle.
  • the delivery vehicle further comprises a payload comprising a therapeutic agent.
  • the therapeutic agent is an RNA, a DNA, or a protein.
  • the therapeutic agent is a nucleic acid encoding a protein of interest selected from the group consisting of a transcription factor, a nuclease for gene editing, a secretion, a receptor, and an antibody or antigen-binding potion thereof.
  • the present technology provides a pharmaceutical composition comprising the delivery vehicle provided herein.
  • the present technology provides a method of conditioning a hematopoietic stem cell (HSC), comprising administering an effective amount of the peptide, the delivery vehicle, or the pharmaceutical composition provided herein.
  • the conditioning comprises promoting division and/or expansion of the HSC.
  • the present technology provides a method of treating a hematologic disorder in a subject in need thereof, comprising administering to the subject a clinically effective amount or a therapeutically effective amount of the peptide, the delivery vehicle, or the pharmaceutical composition provided herein.
  • the hematologic disorder is selected from the group consisting of anemia, hereditary spherocytosis, sickle cell disease (SCD), beta thalassemia, severe combined immunodeficiency (SCID), hemophilia, thrombophilia, and thrombocytopenia.
  • SCD sickle cell disease
  • SCID severe combined immunodeficiency
  • the present technology provides a method of treating a disease associated with cKit in a subject in need thereof, comprising administering to the subject a clinically effective amount or a therapeutically effective amount of the peptide, the delivery vehicle, or the pharmaceutical composition provided herein.
  • the disease associated with cKit is cancer.
  • the cancer is a hematological malignancy selected from the group consisting of monoclonal B cell lymphocytosis, multiple myeloma, myeloid neoplasm, myelodysplastic syndromes (MDS), myeloproliferative/myelodysplastic syndromes, acute lymphoid leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), blast crisis chronic myelogenous leukemia (bcCML), B cell acute lymphoid leukemia (B-ALL), T cell acute lymphoid leukemia (T-ALL), T cell lymphoma, and B cell lymphoma.
  • ALL acute lymphoid leukemia
  • CLL chronic lymphocytic leukemia
  • AML acute myeloid leukemia
  • CML chronic myelogenous leukemia
  • BcCML blast crisis chronic myelogenous leukemia
  • the cancer is a solid tumor selected from the group consisting of lung cancer, breast cancer, liver cancer, stomach cancer, colon cancer, rectal cancer, kidney cancer, gastric cancer, gallbladder cancer, cancer of the small intestine, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, testicular cancer, cancer of the thyroid gland, cancer of the adrenal gland, bladder cancer, and glioma.
  • the disease associated with cKit is an autoimmune disorder selected from the group consisting of type 1 diabetes, lupus, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, Addison’s disease, Graves’ disease, Sjbgren’s syndrome, Hashimoto’s thyroiditis, myasthenia gravis, autoimmune vasculitis, pernicious anemia, and celiac disease.
  • SLE systemic lupus erythematosus
  • the disease associated with cKit is gastrointestinal disorder selected from the group consisting of irritable bowel syndrome (IBS), Crohn’s disease, celiac disease, ulcerative colitis, gas, hemorrhoids, diverticulosis, diverticulitis, gastroesophageal reflux (GER), and gastroesophageal reflux disease (GERD).
  • IBS irritable bowel syndrome
  • Crohn’s disease celiac disease
  • celiac disease ulcerative colitis
  • gas hemorrhoids
  • diverticulosis diverticulitis
  • gastroesophageal reflux GER
  • gastroesophageal reflux disease GABA
  • FIG. 1 shows results of the initial peptide design of PEPTIDE-001 (SEQ ID NO: 1 ), PEPTIDE-002 (SEQ ID NO: 2), and PEPTIDE-003 (SEQ ID NO: 3) based on the extracellular domain of Kit in complex with SCF (PDB ID: 2E9W; SEQ ID NO: 74) from an algorithm with enhanced properties and parameters in accordance with the present technology.
  • FIGS. 2A-2C show solubility charts for peptides PEPTIDE-001 (FIG. 2A), PEPTIDE-002 (FIG. 2B), and PEPTIDE-003 (FIG. 2C) in accordance with the present technology.
  • FIG. 3 depicts the interaction of the C-terminal end of a SCF peptide with cKit in accordance with the present technology.
  • FIG. 4 shows the physiochemical properties of a representative SCF peptide that has been modified at the N-terminal end to replace LP with EE (PEPTIDE-41 ; SEQ ID NO: 41 ) in accordance with the present technology.
  • FIG. 5 depicts the interaction of a representative SCF peptide that has Glu/Arg mutations with cKit in accordance with the present technology.
  • the mutation sites are shown as the dotted regions on the helical structure at the forefront of FIG. 5.
  • peptides designed to specifically target cKit expressed on certain cells can be employed on their own, or, alternatively, on the surface of delivery vehicles, for example, nanoparticles, for targeted delivery of cargos to the cells expressing cKit, thereby modulating cKit signaling and/or cell function via therapeutic agents (e.g., DNA, RNA, protein) in the payload.
  • therapeutic agents e.g., DNA, RNA, protein
  • the present technology can be used in subjects having cKit-implicated diseases including cancer, autoimmune disorders, and gastrointestinal disorders and offers several advantages, including enhanced specificity and efficacy of therapeutic agents targeting the cKit/SCF interaction; reduced off-target effects and toxicity; increased stability and shelf life of the therapeutic complex; and improved patient outcomes and quality of life for diseases linked to cKit/SCF dysfunction.
  • a ratio in the range of about 1 to about 200 should be understood to include the explicitly recited limits of about 1 and about 200, but also to include individual ratios, such as about 2, about 3, and about 4, and sub-ranges, such as about 10 to about 50, about 20 to about 100, and so forth. It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.
  • ranges is intended as a continuous range, including every value between the minimum and maximum values recited, as well as any ranges that may be formed by such values. Also disclosed herein are any and all ratios (and ranges of any such ratios) that may be formed by dividing a disclosed numeric value into any other disclosed numeric value. Accordingly, the skilled person will appreciate that many such ratios, ranges, and ranges of ratios may be unambiguously derived from the numerical values presented herein and in all instances, such ratios, ranges, and ranges of ratios represent various embodiments of the present technology.
  • Compounds having therapeutic applications generated by the present technology include, but are not limited to, peptide ligands of certain receptors. Such compounds are not naturally occurring and are rather designed or otherwise generated by one or more aspects of the present technology. Such peptide ligands may be designed to allosterically and/or orthosterically bind certain receptors.
  • Non-limiting examples of receptors include CD117/ckit (NCBI Gene ID: 3815) and CD34 (NCBI Gene ID: 97).
  • the “peptides” and peptoids described herein can be (a) naturally-occurring, (b) produced by chemical synthesis, (c) produced by recombinant DNA technology, (d) produced by biochemical or enzymatic fragmentation of larger molecules, (e) produced by methods resulting from a combination of methods (a) through (d) listed above, or (f) produced by any other means for producing peptides or recombinant proteins.
  • the term “peptide” as used herein includes any structure comprised of two or more amino acids, including chemical modifications and derivatives of amino acids.
  • amino acids forming all or a part of a peptide may be naturally occurring amino acids, stereoisomers and modifications of such amino acids, non-protein amino acids, post- translationally modified amino acids, enzymatically modified amino acids, constructs or structures designed to mimic amino acids, peptoids, and the like, so that the term “peptide” includes pseudopeptides and peptidomimetics, including structures which have a non- peptidic backbone.
  • the term “peptide” also includes dimers or multimers of peptides.
  • a “manufactured” peptide includes a peptide produced by chemical synthesis, recombinant DNA technology, biochemical, or enzymatic fragmentation of larger molecules, combinations of the foregoing or, in general, made by any other method.
  • peptide includes peptides containing a variable number of amino acid residues, optionally with nonamino acid residue groups at the N- and C-termini, such groups including acyl, acetyl, alkenyl, alkyl, N-alkyl, amine, DBCO, or amide groups, among others.
  • binding refers to all types of physical and chemical binding, reactions, complexing, attraction, chelating and the like.
  • the present technology includes various rationales when selecting an amino acid residue at one or more positions in the peptide ligand, one or more of which may be accounted for when designing such compounds.
  • Rationales for features of the peptide ligand include increase or decrease Gibbs free energy, increase or decrease a Van der Waals effect, additions of one or more linkages, improving solubility, zwitterionic effect with a conjugate, positive to negative amino acid residue ratios between 4/2 and 6/2, non charged polar residue compositions of less than about 20%, aliphatic hydrophobic residues from about 40% to about 50%, aromatic hydrophobic residues and tertiary structures such as beta sheets, location of amino acid residues to promote or inhibit pairing, serum protein corona repulsive behavior, and specific turn character.
  • Percent (%) amino acid sequence “identity” with respect to the sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence for each of the peptides and/or engineered proteins after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity may be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared may be determined.
  • amino acids are molecules containing an amine group, a carboxylic acid group, and a side-chain that is specific to each amino acid.
  • the key elements of an amino acid are carbon, hydrogen, oxygen, and nitrogen and have the generic formula H2N — CHR — COOH, wherein R represents a side chain group.
  • the various a-amino acids differ in the side-chain moiety that is attached to the a-carbon.
  • the “amino acids” of the present technology include the known naturally occurring protein amino acids, which are referred to by both their common three letter abbreviation and single letter abbreviation. See generally Synthetic Peptides: A User’s Guide, G. A. Grant, editor, W.H.
  • amino acid also includes stereoisomers and modifications of naturally occurring protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, derivatized amino acids, constructs or structures designed to mimic amino acids, peptoids, and the like. Modified and unusual amino acids are described generally in Synthetic Peptides: A User’s Guide, supra; Hruby et al., Biochem. J. 268:249-262 (1990); and Toniolo, Int. J. Peptide Protein Res. 35:287-300 (1990); the teachings of all of which are incorporated herein by reference.
  • amino acid side chain moiety used herein, including as used in the specification and claims, includes any side chain of any amino acid, as the term “amino acid” is defined herein. This thus includes the side chain moiety present in naturally occurring amino acids. It further includes side chain moieties in modified naturally occurring amino acids, such as glycosylated amino acids. It further includes side chain moieties in stereoisomers and modifications of naturally occurring protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, derivatized amino acids, constructs, or structures designed to mimic amino acids, and the like. For example, the side chain moiety of any amino acid disclosed herein is included within the definition. A “derivative” of an amino acid side chain moiety is included within the definition of an amino acid side chain moiety.
  • the “derivative” of an amino acid side chain moiety includes any modification to or variation in any amino acid side chain moieties, including a modification of naturally occurring amino acid side chain moieties.
  • derivatives of amino acid side chain moieties include straight chain or branched, cyclic or noncyclic, substituted or unsubstituted, saturated or unsaturated, alkyl, aryl or aralkyl moieties as well as small molecule ligand conjugates.
  • An alpha (a)-amino acid has the generic formula H2N — CaHR — COOH, where R is a side chain moiety and the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (i.e., the a-carbon).
  • R is a side chain moiety and the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (i.e., the a-carbon).
  • Other types of amino acids exist when the amino group is attached to a different carbon atom.
  • beta (P)-amino acids the carbon atom to which the amino group is attached is separated from the carboxylate group by one carbon atom, Cp.
  • a-alanine has the formula H2N — C a H(CH3) — COOH.
  • p-alanine has the general formula H2N — CpH2 — C a H2 — COOH (i.e., 3- aminopropanoic acid).
  • a peptide is most usually acylated at the N-terminus.
  • An “amine” includes compounds that contain an amine group ( — NH2).
  • Amino acids including stereoisomers and modifications of naturally occurring amino acids, protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, derivatized amino acids, constructs, or structures designed to mimic amino acids (peptide mimetics), and the like, including all of the foregoing, are sometimes referred to herein as “residues.”
  • a peptide or amino acid “mimetic” is a non-amino acid molecule that mimics a peptide (a chain of amino acids) or one amino acid residue.
  • variants of the peptide ligands of the present technology may be used.
  • “Variants” include protein sequences having one or more amino acid additions, deletions, stop positions, or substitutions, as compared to a peptide sequence disclosed elsewhere herein.
  • An amino acid substitution may be a conservative or a non-conservative substitution.
  • Variants of the peptide ligands of the present technology include those having one or more conservative amino acid substitutions.
  • a “conservative substitution” or “conservative amino acid substitution” involves a substitution found in one of the following conservative substitutions groups: Group 1 : A, G, S, T; Group 2: E, D; Group 3: N, Q; Group 4: R, K, H; Group 5: I, L, M, V; and Group 6: F, Y, W.
  • amino acids may be grouped into conservative substitution groups by similar function, chemical structure, or composition (e.g., hydrophobic with non-polar side chain, hydrophilic with polar side chain, acidic, basic, aliphatic, aromatic, positively charged, negatively charged, containing a side group such as a conjugation group, a small molecule ligand group, a cross-linking group, or a conjugation site for another molecule on its side group, or sulfur-containing).
  • a side group such as a conjugation group, a small molecule ligand group, a cross-linking group, or a conjugation site for another molecule on its side group, or sulfur-containing.
  • an aliphatic grouping may include, for purposes of substitution, G, A, V, L, and I.
  • Non-conservative substitutions include those that significantly affect: the structure of the peptide backbone in the area of the alteration (e.g., the alpha-helical or betasheet structure); the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain.
  • Non-conservative substitutions which in general are expected to produce the greatest changes in the protein's properties are those in which (i) a hydrophilic residue (e.g. S or T) may be substituted for (or by) a hydrophobic residue (e.g. L, I, F, V, or A); (ii) a C or F may be substituted for (or by) any other residue; (iii) a residue having an electropositive side chain (e.g.
  • K, R, or H may be substituted for (or by) an electronegative residue (e.g. E or D); or (iv) a residue having a bulky side chain (e.g. F), may be substituted for (or by) one not having a bulky side chain, (e.g. G). Additional information is found in Creighton (1984) Proteins, W.H. Freeman and Company.
  • SCF peptides that specifically bind to cKit.
  • These SCF peptides are designed by an artificial intelligence (Al) platform based on the wild-type (WT) sequence of SCF, which is a natural ligand for cKit. After the initial design, the platform can also be used to generate non-naturally occurring mutated SCF peptides with enhanced properties using the parameters listed in Table 1 . See also FIG. 1 .
  • the SCF peptide has the same sequence as wild-type (WT) SCF or a portion thereof.
  • the peptide may have an amino acid sequence of LPSHCWISEMVVQLSDSLTD (SEQ ID NO: 1 ).
  • the SCF peptide may have one or more mutations, deletions, insertions, or other modifications from the WT SCF sequence.
  • Exemplary sequences of SCF peptides targeting cKit are provided in Table 2 below (natural amino acids are highlighted in bold). Solubility of these SCF peptides may be screened using https://pepcalc.com/peptide-solubility-calculator.php. See also FIGS. 2A-2C.
  • SCF peptides can be designed by incorporating one or more unnatural amino acids and/or introducing one or more polyethylene glycol (PEG) or sarcosine (Sar) linkers at the N- and/or C-terminus.
  • Unnatural amino acids used for the present technology can include, but are not limited to, amino-isobutyric acid (Aib) and s-azido-Norleucine (Nle).
  • N-terminal leucine (Leu or L) and proline (Pro or P) (LP) residues are exposed and do not directly interact with cKit.
  • the LP residues of SEQ ID NO: 1 or derived sequences can be replaced with two glutamic acid (Glu or E) residues to improve solubility and/or other characteristics of the SCF peptide.
  • the N- terminal LR residues can be replaced with glutamic acid-arginine (ER), glutamic acid-serine (ES), arginine-arginine (RR), or serine-arginine (SR) residues.
  • the isoelectric point (pl, pH(l), IEP) changes from pH 5.25 to 3.27 (FIG. 2D).
  • the C-terminal end of the SCF peptides designed in accordance with the present technology are not conjugated (FIG. 3). Changes at the C-terminus may result in the SCF peptides’ inability to bind cKit.
  • the cKit-targeting peptide may be conjugated to one or more small molecules or conditioning agents, including, for example, busulfan, saporin, and the like. Conjugation of the peptide with small molecules and/or conditioning agents (optionally small molecule toxins or toxic agents) may be useful as a conditioning approach for ex vivo hematopoietic stem cell (HSC) therapies for treatment of certain blood cancers or hematologic conditions. In some embodiments, such conjugations to conditioning agents could replace or otherwise supplement CD117-antibody drug conjugate (ADC) conditioning regimens for ex vivo HSC therapies.
  • ADC CD117-antibody drug conjugate
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence as set forth in any one of SEQ ID NOs: 1 - 73, or an amino acid sequence that is at least about 80% identical, (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence set forth in any one of SEQ ID NOs: 1 -73.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1 .
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 1.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 2.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 2.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 3.
  • the cKit- targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 3.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 4.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 4.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 5.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 5.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 6.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 6.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 7.
  • the cKit- targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 7.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 8.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 8.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 9.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 9.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 10.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1 1 .
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 1 1.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 12.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 13.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 13.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 14.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 14.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 15.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 15.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 16.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 16.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 17.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 17.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 18.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 19.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 19.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 20.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 21 .
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 22.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 22.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 23.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 23.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 24.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 24.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 25.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 25.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 26.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 26.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 27.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 27.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 28.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 28.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 29.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 29.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SQF peptide) comprises the amino acid sequence of SEQ ID NO: 30.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 31 .
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 32.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 32.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 33.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 33.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 34.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 34.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 35.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 35.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 36.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 36.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 37.
  • the cKit-targeting peptide (e.g., the SQF peptide) comprises the amino acid sequence of SEQ ID NO: 37.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 38.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 38.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 39.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 39.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 40.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 41 .
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 42.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 42.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 43.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 43.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 44.
  • the cKit-targeting peptide (e.g., the SQF peptide) comprises the amino acid sequence of SEQ ID NO: 44.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 45.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 45.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 46.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 46.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 47.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 47.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 48.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 48.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 49.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 49.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 50.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 50.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 51 .
  • the cKit-targeting peptide (e.g., the SQF peptide) comprises the amino acid sequence of SEQ ID NO: 51 .
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 52.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 52.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 53.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 53.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 54.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 54.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 55.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 55.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 56.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 56.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 57.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 57.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 58.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 58.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 59.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 59.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 60.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 1.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 62.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 62.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 63.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 63.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 64.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 64.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 65.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 65.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 66. In some embodiments, the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 66.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 67.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 67.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 68.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 68.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 69.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 69.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 70.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 71 .
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 72.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 72.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises or consists of an amino acid sequence that is at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 73.
  • the cKit-targeting peptide (e.g., the SCF peptide) comprises the amino acid sequence of SEQ ID NO: 73.
  • binding of the cKit-targeting peptide e.g., the SCF peptide
  • cKit expressed on the surface of a target cell alters signal transduction of the cKit receptor (e.g., CD1 17), which may comprise at least partially activating (e.g., when the peptide is an agonist) cKit signaling, at least partially inhibiting or blocking (e.g., when the peptide is an antagonist) cKit signaling, or inhibiting or blocking cKit signaling.
  • delivery vehicles for targeted delivery of payloads (e.g., DNA, RNA, protein) to cells expressing cKit.
  • payloads e.g., DNA, RNA, protein
  • the delivery vehicles may be conjugated to the SCF peptides that specifically bind to cKit according to various embodiments disclosed herein, so that the SCF peptide will function as a targeting ligand and guide the delivery vehicles to target cells with surface expression of cKit.
  • the payloads will then be incorporated into the target cells to achieve their modulating functions.
  • a delivery vehicle is a vehicle for delivering a payload (e.g., nucleic acid and/or protein payload) to a cell.
  • Delivery vehicles can include, but are not limited to, non-viral vehicles, viral vehicles, nanoparticles (e.g., a nanoparticle that includes a targeting ligand and a core comprising an anionic polymer composition, a cationic polymer composition, and/or a cationic polypeptide composition), liposomes, micelles, water-oil-water emulsion particles, oil-water emulsion micellar particles, and multilamellar water-oil-water emulsion particles.
  • a payload e.g., DNA, RNA, protein
  • the delivery vehicle may have a solid core (e.g., metal particle core, quantum dot core, and the like), in which case the payload can be conjugated to (covalently bound to) the core.
  • the delivery vehicle e.g., nanoparticle
  • a payload can be any compound one wishes to deliver to a cell, including, for example, nucleic acids, proteins, and/or ribonucleic acid protein (RNP) complexes.
  • the nucleic acid can be any nucleic acid, linear or circular, and can be a plasmid, a viral genome, an RNA (e.g., mRNA, guide RNA (gRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), and the like), a DNA, or a locked nucleic acid (LNA) molecule.
  • RNA e.g., mRNA, guide RNA (gRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), and the like
  • LNA locked nucleic acid
  • the payload comprises a protein of interest and/or a nucleic acid (e.g., an mRNA) that encodes a protein interest.
  • the protein of interest can be any kind of protein, including, for example, transcription factors; nucleases for gene editing such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, transposases, clustered regularly interspaced short palindromic repeat (CRISPR)/Cas systems, base editors, prime editing systems (e.g., CRISPR/Cas nuclease- reverse transcriptase fusion proteins), and programmable addition via site-specific targeting elements (PASTE) systems (e.g., CRISPR/Cas nuclease-reverse transcriptase-integrase fusion proteins); secretion proteins such as chemokines, chemokines, and immune checkpoint inhibitors; receptors such as chimeric antigen receptors (CARs), C
  • delivery vehicles e.g., nanoparticles decorated with cKit-targeting peptides (SCF peptides) may actively signal the target cells, for example, by signaling gene(s) to be edited inside the target cells, to drive the cells to divide asymmetrically in vivo or ex vivo. This may result in a greater proportion of nanoparticle/payload positive cells (e.g., HSCs) when compared to a non-signaling variant.
  • a secondary set of additional payloads such as miRNAs or cell division factors and their genetic encoded precursors may also be introduced in the delivery vehicles to further expand such cells or push them towards specific differentiation paths.
  • the cKit-targeting peptides (SCF peptides) or delivery vehicle may be present in a pharmaceutical composition.
  • the pharmaceutical composition may further comprise one or more pharmaceutically acceptable carriers, excipients, preservatives, or a combination thereof.
  • pharmaceutically acceptable carriers, excipients, and/or preservatives refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body.
  • the carrier or excipient may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or some combination thereof.
  • Each component of the carrier or excipient must be “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the formulation. It also must be suitable for contact with any tissue, organ, or portion of the body that it may encounter, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.
  • Excipients that may be included in the compositions include, for example, fillers, disintegrants, preserving agents, glidants, lubricants, wetting agents, sweetening agents, flavoring agents, and coloring agents.
  • Such pharmaceutically acceptable excipients may be employed in the compositions to improve processability, palatability, stability, and bioavailability of the composition.
  • Suitable excipients include water, saline, dextrose, glycerol, or the like, and combinations thereof.
  • the pharmaceutical composition may be formulated for different routes of administration, including, for example, systemic administration and local administration.
  • the pharmaceutical composition is formulated for extracorporeal administration, intravenous administration, subcutaneous administration, intralesional administration, intralymphatic administration, intranodal administration, and/or intraperitoneal administration.
  • kits for conditioning cells including hematopoietic stem cells (HSCs), for example, promoting HSC division and expansion comprising administering an effective amount of cKit-targeting peptides (SCF peptides), or delivery vehicles (e.g., nanoparticles) conjugated to cKit- targeting peptides (SCF peptides), according to various embodiments disclosed herein.
  • SCF peptides conjugated of the cKit-targeting peptides (SCF peptides) with small molecules and/or conditioning agents (e.g., small molecule toxins or toxic agents) may be useful as a conditioning approach for HSC therapies.
  • the cKit-targeting peptides (SCF peptides) may be included in cell culture or ex vivo bioreactor medium to promote HSC divisional and expansion.
  • kits for genetically editing cells including HSCs, the methods comprising administering an effective amount of cKit-targeting peptides (SCF peptides), or delivery vehicles (e.g., nanoparticles) conjugated to cKit- targeting peptides (SCF peptides), according to various embodiments disclosed herein.
  • SCF peptides cKit-targeting peptides
  • delivery vehicles e.g., nanoparticles conjugated to cKit- targeting peptides
  • the cKit-targeting peptides may guide the delivery vehicles (e.g., nanoparticles) to target HSCs, and a gene editing system in the payload of the delivery vehicles may exert gene editing functions of the HSCs, so that the genetically corrected HSCs can be used therapeutically for treatment of certain hematologic disorders.
  • delivery vehicles e.g., nanoparticles
  • a gene editing system in the payload of the delivery vehicles may exert gene editing functions of the HSCs, so that the genetically corrected HSCs can be used therapeutically for treatment of certain hematologic disorders.
  • the gene editing system may include any suitable systems depending on the specific need, such as ZFNs, TALENs, meganucleases, transposases, CRISPR/Cas systems, base editors, prime editing systems (e.g., CRISPR/Cas nuclease-reverse transcriptase fusion proteins), and PASTE systems (e.g., CRISPR/Cas nuclease-reverse transcriptase-integrase fusion proteins).
  • delivery vehicles of the present technology may be employed to correct E7V substitution mutations for sickle cell disease (SCD) with base editors; BCL11A knockout for SCD and beta thalassemia with prime editors and PASTE technologies (e.g., Beam, Prime, and Aera tech); and IL2Rgamma correction for severe combined immunodeficiency (SCID).
  • SCD sickle cell disease
  • PASTE technologies e.g., Beam, Prime, and Aera tech
  • SCID severe combined immunodeficiency
  • hematologic disorders include, but are not limited to, anemia, hereditary spherocytosis, SCD, beta thalassemia, SCID, hemophilia, thrombophilia, and thrombocytopenia.
  • a “therapeutically effective amount” as used herein is an amount that produces a desired effect in a subject for an indication, condition, disease, or disorder.
  • the therapeutically effective amount is an amount that yields maximum therapeutic effect.
  • the therapeutically effective amount yields a therapeutic effect that is less than the maximum therapeutic effect.
  • a therapeutically effective amount may be an amount that produces a therapeutic effect while avoiding one or more side effects associated with a dosage that yields maximum therapeutic effect.
  • a therapeutically effective amount for a particular composition will vary based on a variety of factors, including, but not limited to, the characteristics of the therapeutic composition (e.g., activity, pharmacokinetics, pharmacodynamics, and bioavailability); the physiological condition of the subject (e.g., age, body weight, sex, disease type and stage, medical history, general physical condition, responsiveness to a given dosage, and other present medications); the nature of any pharmaceutically acceptable carriers, excipients, and preservatives in the composition; and the route of administration.
  • the characteristics of the therapeutic composition e.g., activity, pharmacokinetics, pharmacodynamics, and bioavailability
  • the physiological condition of the subject e.g., age, body weight, sex, disease type and stage, medical history, general physical condition, responsiveness to a given dosage, and other present medications
  • the nature of any pharmaceutically acceptable carriers, excipients, and preservatives in the composition e.g., a pharmaceutically acceptable carriers, excip
  • a “clinically effective amount,” “clinically effective concentration,” or “clinically effective dose” refers to a concentration or dose of a peptide, composition, or pharmaceutical composition that is shown to be effective in clinical trials or is predicted to be effective based on early phase or pre-clinical trials.
  • a “clinically effective amount” is the same as a “therapeutically effective amount.”
  • a “clinically effective amount” is higher or lower than a “therapeutically effective amount.”
  • kits for treating a disease associated with cKit in a subject in need thereof comprising administering to the subject a clinically effective amount or a therapeutically effective amount of cKit-targeting peptides (SCF peptides), or delivery vehicles (e.g., nanoparticles) conjugated to cKit- targeting peptides (SCF peptides), according to various embodiments disclosed herein.
  • SCF peptides cKit-targeting peptides
  • delivery vehicles e.g., nanoparticles conjugated to cKit- targeting peptides
  • the disease associated with cKit is cancer.
  • the cancer is a hematological malignancy or blood cancer.
  • blood cancers include monoclonal B cell lymphocytosis, multiple myeloma, myeloid neoplasm, myelodysplastic syndromes (MDS), myeloproliferative/myelodysplastic syndromes, acute lymphoid leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), blast crisis chronic myelogenous leukemia (bcCML), B cell acute lymphoid leukemia (B-ALL), T cell acute lymphoid leukemia (T-ALL), T cell lymphoma, and B cell lymphoma.
  • ALL acute lymphoid leukemia
  • CLL chronic lymphocytic leukemia
  • AML acute myeloid leukemia
  • CML chronic myelogenous leukemia
  • the cancer is a solid tumor.
  • solid tumors include lung cancer, breast cancer, liver cancer, stomach cancer, colon cancer, rectal cancer, kidney cancer, gastric cancer, gallbladder cancer, cancer of the small intestine, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, testicular cancer, cancer of the thyroid gland, cancer of the adrenal gland, bladder cancer, and glioma.
  • the disease associated with cKit is an autoimmune disorder.
  • autoimmune diseases include type 1 diabetes, lupus, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, Addison’s disease, Graves’ disease, Sjogren’s syndrome, Hashimoto’s thyroiditis, myasthenia gravis, autoimmune vasculitis, pernicious anemia, and celiac disease.
  • the disease associated with cKit is a gastrointestinal disorder.
  • gastrointestinal disorders include irritable bowel syndrome (IBS), Crohn’s disease, celiac disease, ulcerative colitis, gas, hemorrhoids, diverticulosis, diverticulitis, gastroesophageal reflux (GER), and gastroesophageal reflux disease (GERD).
  • the method comprises administration of at least one dose of the cKit-targeting peptides (SCF peptides). In some embodiments, the method comprises administration of multiple doses (e.g., two doses, three doses, four doses, five doses, or more than five doses) of the cKit-targeting peptides (SCF peptides).
  • the method comprises administration of at least one dose of the targeted delivery vehicles (e.g., delivery vehicles (e.g., nanoparticles) conjugated to cKit-targeting peptides (SCF peptides)).
  • the method comprises administration of multiple doses (e.g., two doses, three doses, four doses, five doses, or more than five doses) of the targeted delivery vehicles.
  • the cKit-targeting peptides are administered systemically. In some embodiments, the targeted delivery vehicles are administered locally. In some embodiments, the cKit-targeting peptides (SCF peptides) are administered by extracorporeal administration, intravenous administration, subcutaneous administration, intralesional administration, intralymphatic administration, intranodal administration, or intraperitoneal administration. In some embodiments, the cKit-targeting peptides (SCF peptides) are delivered preferentially to a tumor or other diseased tissue, for example, by local injection or intralesional injection.
  • the targeted delivery vehicles are administered systemically. In some embodiments, the targeted delivery vehicles are administered locally. In some embodiments, the targeted delivery vehicles are administered by extracorporeal administration, intravenous administration, subcutaneous administration, intralesional administration, intralymphatic administration, intranodal administration, or intraperitoneal administration. In some embodiments, the targeted delivery vehicles are delivered preferentially to a tumor or other diseased tissue, for example, by local injection or intralesional injection.
  • the cKit-targeting peptides are administered to the subject in a range of from about 0.1 mg/kg to about 30 mg/kg (dose corresponding to payload), from 0.1 mg/kg to about 10 mg/kg, from 0.1 mg/kg to about 3 mg/kg, for example, at a dose of about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, 15 mg/kg, about 20 mg/kg, about 25 mg/kg, or about 30 mg/kg.
  • the targeted delivery vehicles are administered to the subject in a range of from about 0.1 mg/kg to about 30 mg/kg (dose corresponding to payload), from 0.1 mg/kg to about 10 mg/kg, from 0.1 mg/kg to about 3 mg/kg, for example, at a dose of about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, 15 mg/kg, about 20 mg/kg, about 25 mg/kg, or about 30 mg/kg.
  • the cKit-targeting peptides are administered to the subject once a day or twice a day for a period of about 1 day, about 2 days, about 3 days, about 5 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 1 1 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or more than about 5 years.
  • the cKit-targeting peptides may be administered every day, every other day, 3 times a week, every third day, weekly, biweekly (i.e., every other week), every third week, monthly, every other month, every third month, every fourth month, every fifth month, every sixth month, every ninth month, every year, every 18 months, every 2 years, every 5 years, every 10 years, or every 20 years.
  • the dose regimens listed above could be repeated after a period of about 1 week, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or more than about 5 years.
  • treatment is continued until disease is eliminated, until no further improvement Is achieved, or as long as the disease does not progress.
  • the targeted delivery vehicles are administered to the subject once a day or twice a day for a period of about 1 day, about 2 days, about 3 days, about 5 days, about 7 days, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or more than about 5 years.
  • the targeted delivery vehicles may be administered every day, every other day, 3 times a week, every third day, weekly, biweekly (i.e., every other week), every third week, monthly, every other month, every third month, every fourth month, every fifth month, every sixth month, every ninth month, every year, every 18 months, every 2 years, every 5 years, every 10 years, or every 20 years.
  • the dose regimens listed above could be repeated after a period of about 1 week, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 1 1 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or more than about 5 years.
  • treatment is continued until disease is eliminated, until no further improvement is achieved, or as long as the disease does not progress.
  • Example 1 Initial Peptide Design [0094] Using a proprietary Al platform, exemplary SCF peptides (SEQ ID NOs: 1 -3) were designed against the cKit receptor. After the initial design, an updated version of the platform was used to design mutated SCF peptides with enhanced properties using the parameters listed in Table 1. The resulting peptides are shown in FIG. 1 and Table 2 as PEPTIDE-001 (SEQ ID NO: 1 ), PEPTIDE-002 (SEQ ID NO: 2), and PEPTIDE-003 (SEQ ID NO: 3). FIG. 1 also provides the sequence of the extracellular domain of Kit in complex with SCF (EGICRNRVTNNVKDVTKLVANLPKDYMITLKYVPGMDVLPSHCWISEMVVQLSDSL TDLLDKFS; SEQ ID NO: 74)
  • Additional peptides were designed to incorporate both unnatural amino acids (e.g., amino-isobutyric acid (Aib) and e-azido-norleucine (Nle)) and/or a polyethylene glycol (PEG) or sarcosine (Sar) linker.
  • unnatural amino acids e.g., amino-isobutyric acid (Aib) and e-azido-norleucine (Nle)
  • PEG polyethylene glycol
  • Sar sarcosine
  • FIG. 3 depicts the interaction of the C-terminal end of a representative SCF peptide with cKit. Due to this interaction, SCF peptides that modified to include conjugation at the C-terminal end (e.g., SEQ ID NOs: 34, 35, 38, and 39) may have decreased ability to bind to cKit.
  • SCF peptides that modified to include conjugation at the C-terminal end e.g., SEQ ID NOs: 34, 35, 38, and 39
  • SEQ ID NOs: 34, 35, 38, and 39 may have decreased ability to bind to cKit.
  • FIG. 4 shows the physiochemical properties of a representative SCF peptide that has been modified at the N- terminal end to replace LP with EE (PEPTIDE-41 ; SEQ ID NO: 41 ). As shown in FIG. 4, such modification decreased the isoeletric point (I EP) of the representative SCF peptide from pH 5.25 to 3.27. Thus, replacing the N-terminal terminal LP resides may eliminate the need for other peptides where Aib is replaced for the terminal Leu.
  • FIG. 5 depicts the interaction of a representative SCF peptide that has Glu/Arg mutations with cKit.
  • the mutation sites are shown as the dotted regions on the helical structure at the forefront of FIG. 5.
  • a peptide that specifically targets cKit wherein the peptide comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1 -73, or an amino acid sequence that is at least 80% identical to any one of SEQ ID NOs: 1 -73.
  • RNA RNA, a DNA, or a protein.
  • the therapeutic agent is a nucleic acid encoding a protein of interest selected from the group consisting of a transcription factor, a nuclease for gene editing, a secretion, a receptor, and an antibody or antigen-binding potion thereof.
  • a pharmaceutical composition comprising the peptide of any one of embodiments 1 -5 or the delivery vehicle of any one of embodiments 6-10.
  • a method of conditioning a hematopoietic stem cell comprising administering an effective amount of the peptide of any one of embodiments 1 -5, the delivery vehicle of any one of embodiments 6-10, or the pharmaceutical composition of embodiment 1 1.
  • a method of treating a hematologic disorder in a subject in need thereof comprising administering to the subject a clinically effective amount or a therapeutically effective amount of the peptide of any one of embodiments 1 -5, the delivery vehicle of any one of embodiments 6-10, or the pharmaceutical composition of embodiment 1 1 .
  • hematologic disorder is selected from the group consisting of anemia, hereditary spherocytosis, sickle cell disease (SCD), beta thalassemia, severe combined immunodeficiency (SCID), hemophilia, thrombophilia, and thrombocytopenia.
  • SCD sickle cell disease
  • SCID severe combined immunodeficiency
  • a method of treating a disease associated with cKit in a subject in need thereof comprising administering to the subject a clinically effective amount or a therapeutically effective amount of the peptide of any one of embodiments 1 -5, the delivery vehicle of any one of embodiments 6-10, or the pharmaceutical composition of embodiment 1 1.
  • the disease associated with cKit is cancer.
  • cancer is a hematological malignancy selected from the group consisting of monoclonal B cell lymphocytosis, multiple myeloma, myeloid neoplasm, myelodysplastic syndromes (MDS), myeloproliferative/myelodysplastic syndromes, acute lymphoid leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), blast crisis chronic myelogenous leukemia (bcCML), B cell acute lymphoid leukemia (B-ALL), T cell acute lymphoid leukemia (T-ALL), T cell lymphoma, and B cell lymphoma.
  • ALL acute lymphoid leukemia
  • CLL chronic lymphocytic leukemia
  • AML acute myeloid leukemia
  • CML chronic myelogenous leukemia
  • BcCML blast crisis chronic myelogenous leukemia
  • cancer is a solid tumor selected from the group consisting of lung cancer, breast cancer, liver cancer, stomach cancer, colon cancer, rectal cancer, kidney cancer, gastric cancer, gallbladder cancer, cancer of the small intestine, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, testicular cancer, cancer of the thyroid gland, cancer of the adrenal gland, bladder cancer, and glioma.
  • lung cancer breast cancer, liver cancer, stomach cancer, colon cancer, rectal cancer, kidney cancer, gastric cancer, gallbladder cancer, cancer of the small intestine, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, testicular cancer, cancer of the thyroid gland, cancer of the adrenal gland, bladder cancer, and glioma.
  • the disease associated with cKit is an autoimmune disorder selected from the group consisting of type 1 diabetes, lupus, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, Addison’s disease, Graves’ disease, Sjogren’s syndrome, Hashimoto’s thyroiditis, myasthenia gravis, autoimmune vasculitis, pernicious anemia, and celiac disease.
  • SLE systemic lupus erythematosus
  • hematologic disorder is selected from the group consisting of anemia, hereditary spherocytosis, sickle cell disease (SCD), beta thalassemia, severe combined immunodeficiency (SCID), hemophilia, thrombophilia, and thrombocytopenia.
  • SCD sickle cell disease
  • SCID severe combined immunodeficiency
  • cancer is a hematological malignancy selected from the group consisting of monoclonal B cell lymphocytosis, multiple myeloma, myeloid neoplasm, myelodysplastic syndromes (MDS), myeloproliferative/myelodysplastic syndromes, acute lymphoid leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), blast crisis chronic myelogenous leukemia (bcCML), B cell acute lymphoid leukemia (B-ALL), T cell acute lymphoid leukemia (T-ALL), T cell lymphoma, and B cell lymphoma.
  • ALL acute lymphoid leukemia
  • CLL chronic lymphocytic leukemia
  • AML acute myeloid leukemia
  • CML chronic myelogenous leukemia
  • BcCML blast crisis chronic myelogenous leukemia
  • cancer is a solid tumor selected from the group consisting of lung cancer, breast cancer, liver cancer, stomach cancer, colon cancer, rectal cancer, kidney cancer, gastric cancer, gallbladder cancer, cancer of the small intestine, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, testicular cancer, cancer of the thyroid gland, cancer of the adrenal gland, bladder cancer, and glioma.
  • lung cancer breast cancer, liver cancer, stomach cancer, colon cancer, rectal cancer, kidney cancer, gastric cancer, gallbladder cancer, cancer of the small intestine, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, uterine cancer, ovarian cancer, testicular cancer, cancer of the thyroid gland, cancer of the adrenal gland, bladder cancer, and glioma.
  • the disease associated with cKit is an autoimmune disorder selected from the group consisting of type 1 diabetes, lupus, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, Addison’s disease, Graves’ disease, Sjogren’s syndrome, Hashimoto’s thyroiditis, myasthenia gravis, autoimmune vasculitis, pernicious anemia, and celiac disease. [0129] 29.
  • SLE systemic lupus erythematosus
  • embodiment 24 wherein the disease associated with cKit is gastrointestinal disorder selected from the group consisting of irritable bowel syndrome (IBS), Crohn’s disease, celiac disease, ulcerative colitis, gas, hemorrhoids, diverticulosis, diverticulitis, gastroesophageal reflux (GER), and gastroesophageal reflux disease (GERD).
  • IBS irritable bowel syndrome
  • Crohn’s disease celiac disease
  • celiac disease ulcerative colitis
  • gas hemorrhoids
  • diverticulosis diverticulitis
  • gastroesophageal reflux GER
  • gastroesophageal reflux disease GABA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente technologie concerne des peptides SCF conçus pour cibler spécifiquement cKit, des véhicules de délivrance (par exemple, des nanoparticules) conjugués à des peptides ciblant cKit (par exemple, des peptides SCF) pour délivrance de charges utiles thérapeutiques à des cellules exprimant cKit, ainsi que des méthodes d'utilisation de ceux-ci pour traiter diverses maladies dont le cancer, des troubles auto-immuns et des troubles gastro-intestinaux.
PCT/US2024/019186 2023-03-10 2024-03-08 Peptides ciblant ckit utilisés comme agent thérapeutique et leurs procédés d'utilisation Ceased WO2024191848A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24771486.8A EP4676943A2 (fr) 2023-03-10 2024-03-08 Peptides ciblant ckit utilisés comme agent thérapeutique et leurs procédés d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363489666P 2023-03-10 2023-03-10
US63/489,666 2023-03-10

Publications (2)

Publication Number Publication Date
WO2024191848A2 true WO2024191848A2 (fr) 2024-09-19
WO2024191848A3 WO2024191848A3 (fr) 2024-11-07

Family

ID=92756337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/019186 Ceased WO2024191848A2 (fr) 2023-03-10 2024-03-08 Peptides ciblant ckit utilisés comme agent thérapeutique et leurs procédés d'utilisation

Country Status (2)

Country Link
EP (1) EP4676943A2 (fr)
WO (1) WO2024191848A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2657113B2 (ja) * 1989-10-16 1997-09-24 アムジエン・インコーポレーテツド 幹細胞因子
WO2018183613A1 (fr) * 2017-03-31 2018-10-04 The Children's Medical Center Corporation Conditionnement médié par anticorps avec immunosuppression pour permettre une greffe allogénique

Also Published As

Publication number Publication date
EP4676943A2 (fr) 2026-01-14
WO2024191848A3 (fr) 2024-11-07

Similar Documents

Publication Publication Date Title
US11944688B2 (en) Biologically active compounds
US10961292B2 (en) Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof
JP5734865B2 (ja) 選択性に優れた抗がんキメラペプチド
CA2632451C (fr) Peptides de penetration cellulaire pour la delivrance intracellulaire de molecules
AU2020256311B2 (en) ATF5 peptide variants and uses thereof
EP3749678A1 (fr) Modules peptidiques agrafés perméables aux cellules pour administration cellulaire
US12162959B2 (en) Cyclic peptide for treating cancer
KR20220167770A (ko) 타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드-지질의 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
JP2023145635A (ja) 免疫調節特性を有するペプチド
JP7663249B2 (ja) 改変型ｂｃｌ９模倣ペプチド
Futami et al. Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery
EP4676943A2 (fr) Peptides ciblant ckit utilisés comme agent thérapeutique et leurs procédés d'utilisation
EP1795539B1 (fr) Peptides pénétrant dans les cellules à délivrance intracellulaire des molecules
WO2025049691A1 (fr) Molécules de revêtement à base de peptides pour stabiliser des nanostructures d'adn et conférer une activité biologique
KR20250138134A (ko) 표적 단백질 분해자 및 세포 투과 펩타이드를 포함하는 융합 분자 및 이의 용도
WO2020230122A1 (fr) Peptides pour le traitement du cancer
HK40040895B (en) Atf5 peptide variants and uses thereof
HK40040895A (en) Atf5 peptide variants and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24771486

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024771486

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024771486

Country of ref document: EP

Effective date: 20251010

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24771486

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024771486

Country of ref document: EP

Effective date: 20251010

ENP Entry into the national phase

Ref document number: 2024771486

Country of ref document: EP

Effective date: 20251010

ENP Entry into the national phase

Ref document number: 2024771486

Country of ref document: EP

Effective date: 20251010